Author (year) | Design | No. of pts. | Clinical condition & indication | Dose prescription, median (range), Gy/fractions | LC, % | OS, % | Toxicity | |||
---|---|---|---|---|---|---|---|---|---|---|
PVTT | Tumor size, median (range), cm | CP class | Liver | GI | ||||||
Andolino [9] (2011) | Phase I/II | 60 | NA | 3.1 (1.0–6.5) | A,B | CP-A: 44/3 (30–48) CP-B: 40/5 (24–48) | 90 (2Y) | 67 (2Y) | CP class change: 20% (A➔B: 12%, B➔A: 8%) Hepatic failure: 7% (all with a CP score ≥ 8) | No GI toxicity ≥ G3 |
Kang [12] (2012) | Phase II | 47 | Yes (11%) | 2.9 (1.3–7.8) (sum of size) | A,B7 | 57/3 (42–60/3) | 95 (2Y) | 69 (2Y) | No RILD CP class change A➔B: 13% | GI toxicity G3: 6% Gastric ulcer G4: 4% |
Yoon [8] (2013) | Retro | 93 | No | 2 (1.0–6.0) | A, B | 45/3 (30–60/3–4) | 95 (1Y) 92 (3Y) | 86 (1Y) 54 (3Y) | RILD ≥ G2: 18% (≥ G3: 7%) Worsening of CP score ≥ 2: 10% | No bleeding or perforation |
Sanuki [7] (2014) | Retro | 185 | NA | CP-A: 2.4 (0.5–5.0) CP-B: 2.7 (1.0–5.0) | A, B | CP-A: 40/5 CP-B: 35/5 | 99 (1Y)91 (3Y) | 95 (1Y) 70 (3Y) | Worsening of CP score ≥ 2: 10% G5 hepatic failure: 1% | NA |
Huertas [21] (2015) | Retro | 77 | NA | 2.4 (0.7–6.3) | A, B8 | 45/3 | 99 (1Y) 97 (3Y) | 99 (1Y) 84 (3Y) | RILD: 5% | Gastric ulcer G3: 1%, G4: 1% Colic ulcer G2: 1% |
Katz [25] (2011) | Retro | 18 | No | 4.0 (1.2–6.5) | A, B, C | 50/10 | 9% of patients developed a new lesion within 12 months after transplantation | 100% after LT and/or hepatic resection (median follow up 19.6 months) | Elevated liver enzyme G3: 5.6% | No GI toxicity ≥ G3 |
Bae [24] (2012) | Retro | 20 | No | < 5 cm (≤ 3 cm: 80%, > 3 cm: 20%) | A,B | 50/10 | 85 (2Y) | 88 (2Y) | No RILD ≥ G3 | GI toxicity G1: 30% No GI toxicity ≥ G3 |
Present study | Retro | 77 | No | 2.4 (0.8–5.6) | A, B | 50/10 (35–50/10) | 80 (3Y) 73 (5Y) | 52 (3Y) 41 (5Y) | Worsening of CP score ≥ 2: 5.2% | GI bleeding G3: 1.3% |